

should read: Interested manufacturers should submit a letter of interest with information about their capabilities to the following e-mail address: [esli@cdc.gov](mailto:esli@cdc.gov).

On page 48499 under the heading **FOR FURTHER INFORMATION CONTACT** change to read: [esli@cdc.gov](mailto:esli@cdc.gov).

Dated: August 25, 2004.

**James D. Seligman,**

*Associate Director for Program Services, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 04-19931 Filed 8-31-04; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, Announces the Following Meeting

*Name:* ICD-9-CM Coordination and Maintenance Committee meeting.

*Times and Dates:* 9 a.m.-4 p.m., October 7-8, 2004.

*Place:* Centers for Medicare and Medicaid Services (CMS) Auditorium, 7500 Security Boulevard, Baltimore, Maryland.

*Status:* Open to the public.

*Purpose:* The ICD-9-CM Coordination and Maintenance (C&M) Committee will hold its final meeting of the 2004 calendar year cycle on Thursday and Friday, October 7-8, 2004. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Ninth-Revision, Clinical Modification.

*Matters To Be Discussed:* Agenda items include:

Diabetic peripheral neuropathy, diabetic retinopathy and diabetic macular edema.

Renal failure, continued.

At-risk for perioperative myocardial ischemia.

Mechanical complication of joint prosthesis.

Metabolic disorders.

Refractory anemia.

Insomnia and hypersomnia.

ICD-10-Procedure Classification System (PCS)—Update.

Revision of hip replacement.

Revision of knee replacement.

Sublingual Capnometry.

Implantation of prosthetic cardiac support device.

Multiple vessel drug-eluting stent.

Revision of CRT-D pocket.

Insertion of rechargeable neurostimulator pulse generator.

Infusion of liquid radioisotope for treatment of malignant brain tumor.

Addenda.

*Contact Person for Additional Information:* Amy Blum, Medical Classification Specialist, Classifications and Public Health Data Standards Staff, NCHS, 3311 Toledo Road, Room 2402, Hyattsville, Maryland 20782, telephone 301-458-4106 (diagnosis), Amy Gruber, Health Insurance Specialist, Division of Acute Care, CMS, 7500 Security Blvd., Room C4-07-07, Baltimore, Maryland, 21244, telephone 410-786-1542 (procedures).

*Notice:* In the interest of security, CMS has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

Because of increased security requirements, those who wish to attend a specific ICD-9-CM C&M meeting in the CMS auditorium must submit their name and organization for addition to the meeting visitor list. Those wishing to attend the October 7-8, 2004 meeting must submit their name and organization by October 4, 2004 for inclusion on the visitor list. This visitor list will be maintained at the front desk of the CMS building and used by the guards to admit visitors to the meeting. Those who attended previous ICD-9-CM C&M meetings will no longer be automatically added to the visitor list. You must request inclusion of your name prior to each meeting you attend.

Send your name and organization to one of the following by October 4, 2004 in order to attend the October 7-8, 2004 meeting: Pat Brooks, [pbrooks1@cms.hhs.gov](mailto:pbrooks1@cms.hhs.gov), 410-786-5318. Ann Fagan, [afagan@cms.hhs.gov](mailto:afagan@cms.hhs.gov), 410-786-5662. Amy Gruber, [agruber@cms.hhs.gov](mailto:agruber@cms.hhs.gov), 410-786-1542.

*Notice:* This is a public meeting. However, because of fire code requirements, should the number of attendants meet the capacity of the room, the meeting will be closed.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: August 25, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 04-19945 Filed 8-31-04; 8:45 am]

**BILLING CODE 4160-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2003N-0455]

#### Training Program for Regulatory Project Managers; Information Available to Industry

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) is announcing the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program (the Site Tours Program). This training program was initiated in 1999, and it is intended to give CDER regulatory project managers an opportunity to tour pharmaceutical facilities and to exchange regulatory experiences with their industry counterparts. The Site Tours Program is intended to enhance review efficiency and quality by providing CDER staff with a better understanding of the pharmaceutical industry and its operations. Further, this program is intended to improve communication and cooperation between CDER staff and industry. The purpose of this notice is to invite pharmaceutical companies interested in participating in these programs to contact CDER.

**DATES:** Pharmaceutical companies may submit proposed agendas to the agency by November 1, 2004.

**FOR FURTHER INFORMATION CONTACT:** Beth Duvall-Miller, Office of New Drugs (HFD-020), Center for Drug Evaluation and Research, Food and Drug Administration, 5515 Security Lane, rm. 7219, Rockville, MD 20852, 301-594-3937, FAX: 301-480-8329.

#### SUPPLEMENTARY INFORMATION:

##### I. Background

An important part of CDER's commitment to make safe and effective drugs available to all Americans is optimizing the efficiency and quality of the drug review process. To support this primary goal, the center has initiated various training and development programs to promote high performance